A Phase 2 interventional study of Dupilumab in Peanut Allergy, sponsored by Regeneron Pharmaceuticals. Completed at 9 sites in 2 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-05-19.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Peanut Hypersensitivity with a site in United States — 10 open to participants now, 16 under way, 3 of them phase 3. Peanut Hypersensitivity · United States.
Among the 99 studies in Peanut Hypersensitivity with a site in United States, this one is the 61st largest by enrollment of the 87 interventional ones that give a count, is one of 6 that started in 2019, is one of 26 in phase 2, and was the 63rd registered.
166 studies on the registry are indexed under Peanut Hypersensitivity; 27 are open to participants now.
Browse Peanut Hypersensitivity studies →10 of the 99 studies in Peanut Hypersensitivity with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 12–65
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12 mo–17 yrs
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12–55
N-Fold, LLC · Sites in United States
Ages 14–50 · Healthy volunteers
Mabylon AG · Sites in United States
Ages 12–55 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Peanut Hypersensitivity studies recruiting now, 2 (11%) set no upper age limit and 16 (89%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 43 · Phase 3 17
First in 1996; this study’s year is marked. 6 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 50 across 127 interventional studies indexed under Peanut Hypersensitivity.
Median enrollment 47 across the 87 interventional studies, 270 across the 11 observational. Of the 77 that completed or were terminated, 50 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 99 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 2 studies filed under Peanut Hypersensitivity — fewer than ten, so there is no comparison to draw.
6 of the studies in Peanut Hypersensitivity with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07003919Phase 3DBV TechnologiesSafety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | 2026-11 |
| NCT05476497Allergy TherapeuticsPhase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects | 2026-11 |
| NCT04222491Massachusetts General HospitalFood Oral Immunotherapy for Peanut Allergy | 2026-12 |
| NCT05695261Rima RachidEvaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients | 2027-01-11 |
| NCT07220811RAPT Therapeutics, Inc., a member of the GSK plc group of companiesPhase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy | 2027-03-16 |
Add all 6 to your calendar (.ics) → With an account.
Among the 99 studies in Peanut Hypersensitivity with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to assess the tolerability of peanut protein in pediatric patients (6-17 years old) treated with dupilumab monotherapy, in which tolerability is defined as the proportion of patients who safely pass a double-blind placebo-controlled food challenge (DBPCFC) at week 24.
The secondary objectives are:
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol Inclusion/Exclusion Criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open label weight base subcutaneous (SC) injection every two (Q2) weeks.
Drug: Dupilumab
Dupilumab weight-based dosing will be administered subcutaneously (SC) in a single-use, pre-filled syringe every two weeks (Q2W)
Also known as: REGN668, IL4R, Dupixent, SAR231893
Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 444 mg (Cumulative) Peanut Protein at Week 24
Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants treated with dupilumab who passed the DBPCFC with at least 444 mg (cumulative) peanut protein at Week 24 was reported.
Time frame: At Week 24
Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Weeks 24 and 36
Change from baseline in cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC at Week 24 and Week 36 was reported.
Time frame: Weeks 24 and 36
Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 444 mg (Cumulative) Peanut Protein at Week 36
Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Only participants treated with dupilumab who passed at least 444 mg (cumulative) peanut challenge at Week 24 were eligible for Week 36 DBFC.
Time frame: At Week 36
Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 1044 mg (Cumulative) Peanut Protein at Week 24
Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants treated with dupilumab who passed a DBPCFC with at least 1044 mg (cumulative) peanut protein at Week 24 was reported.
Time frame: At Week 24
Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 1044 mg (Cumulative) Peanut Protein at Week 36
Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Only participants treated with dupilumab who passed at least 444 mg (cumulative) peanut challenge at Week 24 were eligible for Week 36 DBFC.
Time frame: At Week 36
Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 2044 mg (Cumulative) Peanut Protein at Week 24
Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants treated with dupilumab who passed a DBPCFC with at least 2044 mg (cumulative) peanut protein at Week 24 was reported.
Time frame: At Week 24
Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 2044 mg (Cumulative) Peanut Protein at Week 36
Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Only participants treated with dupilumab who passed at least 444 mg (cumulative) peanut challenge at Week 24 were eligible for Week 36 DBFC.
Time frame: At Week 36
Percent Change From Baseline in Peanut-specific Immunoglobulin E (sIgE) at Weeks 4, 8, 12, 16, 24, and 36
Percent change from baseline in sIgE at Weeks 4, 8, 12, 16, 24, and 36 was reported.
Time frame: Weeks 4, 8, 12, 16, 24, and 36
Change From Baseline in Titrated Skin Prick Test (SPT) Measured by Average Wheal Size Area Under the Curve (AUC) After Peanut Allergen Stimulation at Different Concentrations at Weeks 4, 12, 24, and 36
The titrated SPT is the skin testing for atopic response at different concentrations of peanut extract with saline as negative control and histamine as positive controls. Wheal size induced by peanut extract at each concentration was calculated as average of largest diameter and perpendicular midpoint diameter. The AUC for titrated SPT was calculated using the mean wheal diameter versus the concentration at which the wheal diameter was measured, which was then normalized to concentration. Change from baseline in titrated SPT as measured by average wheal size AUC after peanut allergen stimulation at different concentrations at Weeks 4, 12, 24, and 36 was reported.
Time frame: Weeks 4, 12, 24, and 36
Percentage of Participants With Grade 2 or Above Allergic Reactions During the DBPCFC at Week 24
Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Percentage of participants with Grade 2 (Moderate) or above allergic reactions during the DBPCFC at Week 24 was reported.
Time frame: At Week 24
Percentage of Participants Who Used Epinephrine as a Rescue Medication During the DBPCFC at Week 24
Percentage of participants who used Epinephrine as a rescue medication during the DBPCFC at Week 24 was reported.
Time frame: At Week 24
Twenty-five participants met eligibility criteria. One of the 25 participants was randomized under the original double-blind placebo-controlled protocol and received placebo-matching dupilumab. Following implementation of Protocol Amendment 1, 24 participants were enrolled under the open-label design \& received open-label treatment with dupilumab.
| Milestone | Placebo | Dupilumab |
|---|---|---|
| Started | 1 | 24 |
| Treated | 1 | 24 |
| Safety analysis set (saf) | 0 | 24 |
| Completed | 1 | 24 |
| Not completed | 0 | 0 |
Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants treated with dupilumab who passed the DBPCFC with at least 444 mg (cumulative) peanut protein at Week 24 was reported.
| Percentage of Participants | Dupilumab |
|---|---|
| Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 444 mg (Cumulative) Peanut Protein at Week 24 | 8.3 (1.03 to 27.00) |
Change from baseline in cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC at Week 24 and Week 36 was reported.
| Log Transformed Milligrams | Dupilumab |
|---|---|
| Change at Week 24 | 0.69 ± 1.822 |
| Change at Week 36 | 3.38 ± 3.096 |
Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Only participants treated with dupilumab who passed at least 444 mg (cumulative) peanut challenge at Week 24 were eligible for Week 36 DBFC.
| Percentage of Participants | Dupilumab |
|---|---|
| Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 444 mg (Cumulative) Peanut Protein at Week 36 | 50.0 |
Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants treated with dupilumab who passed a DBPCFC with at least 1044 mg (cumulative) peanut protein at Week 24 was reported.
| Percentage of Participants | Dupilumab |
|---|---|
| Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 1044 mg (Cumulative) Peanut Protein at Week 24 | 0.0 (0.00 to 14.25) |
Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Only participants treated with dupilumab who passed at least 444 mg (cumulative) peanut challenge at Week 24 were eligible for Week 36 DBFC.
| Percentage of Participants | Dupilumab |
|---|---|
| Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 1044 mg (Cumulative) Peanut Protein at Week 36 | 50.0 |
Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants treated with dupilumab who passed a DBPCFC with at least 2044 mg (cumulative) peanut protein at Week 24 was reported.
| Percentage of Participants | Dupilumab |
|---|---|
| Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 2044 mg (Cumulative) Peanut Protein at Week 24 | 0.0 (0.00 to 14.25) |
Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Only participants treated with dupilumab who passed at least 444 mg (cumulative) peanut challenge at Week 24 were eligible for Week 36 DBFC.
| Percentage of Participants | Dupilumab |
|---|---|
| Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 2044 mg (Cumulative) Peanut Protein at Week 36 | 0.0 |
Percent change from baseline in sIgE at Weeks 4, 8, 12, 16, 24, and 36 was reported.
| Percent Change | Dupilumab |
|---|---|
| Percent change at Week 4 | -7.86 (-19.75 to -1.62) |
| Percent change at Week 8 | -21.03 (-33.45 to -10.37) |
| Percent change at Week 12 | -32.10 (-40.92 to -11.14) |
| Percent change at Week 16 | -32.22 (-47.75 to -16.17) |
| Percent change at Week 24 | -49.25 (-61.22 to -31.85) |
| Percent change at Week 36 | -58.43 (-71.25 to -45.17) |
The titrated SPT is the skin testing for atopic response at different concentrations of peanut extract with saline as negative control and histamine as positive controls. Wheal size induced by peanut extract at each concentration was calculated as average of largest diameter and perpendicular midpoint diameter. The AUC for titrated SPT was calculated using the mean wheal diameter versus the concentration at which the wheal diameter was measured, which was then normalized to concentration. Change from baseline in titrated SPT as measured by average wheal size AUC after peanut allergen stimulation at different concentrations at Weeks 4, 12, 24, and 36 was reported.
| millimeter (mm) | Dupilumab |
|---|---|
| Change at Week 4 | -0.633 ± 2.0604 |
| Change at Week 12 | -0.174 ± 2.0618 |
| Change at Week 24 | -0.232 ± 2.0610 |
| Change at Week 36 | -0.364 ± 2.1419 |
Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The scale is Grade 1 (Mild) through 5, the higher the grade, the more severe the allergic reaction. Percentage of participants with Grade 2 (Moderate) or above allergic reactions during the DBPCFC at Week 24 was reported.
| Percentage of Participants | Dupilumab |
|---|---|
| Percentage of Participants With Grade 2 or Above Allergic Reactions During the DBPCFC at Week 24 | 33.3 |
Percentage of participants who used Epinephrine as a rescue medication during the DBPCFC at Week 24 was reported.
| Percentage of Participants | Dupilumab |
|---|---|
| Percentage of Participants Who Used Epinephrine as a Rescue Medication During the DBPCFC at Week 24 | 41.7 |
Collected over Up to the end of study (Week 36). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Dupilumab | 0/24 (0%) | 0/24 (0%) | 11/24 (45.8%) |
| Event | Placebo | Dupilumab |
|---|---|---|
| Injection site painGeneral disorders | 0/1 | 3/24 |
| Injection site urticariaGeneral disorders | 0/1 | 3/24 |
| HeadacheNervous system disorders | 0/1 | 3/24 |
| Injection site erythemaGeneral disorders | 0/1 | 2/24 |
| Injection site haemorrhageGeneral disorders | 0/1 | 2/24 |
| Injection site reactionGeneral disorders | 0/1 | 2/24 |
| Medical device painGeneral disorders | 0/1 | 2/24 |
| Upper respiratory tract infectionInfections and infestations | 0/1 | 2/24 |
| ContusionInjury, poisoning and procedural complications | 0/1 | 2/24 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/1 | 2/24 |
SAF(all participants who received dupilumab)
| Age, Continuous(Years) | Dupilumab |
|---|---|
| Mean | 11.7 ± 3.28 |
| Sex: Female, Male(Participants) | Dupilumab |
|---|---|
| Female | 6 |
| Male | 18 |
| Ethnicity (NIH/OMB)(Participants) | Dupilumab |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 22 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Dupilumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 19 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All IPD that underlie results in a publication
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Individual de-identified participant data will be made available once the indication has been approved by a regulatory body, if there is participant consent and there is not a reasonable likelihood of participant re-identification.
Access criteria: Qualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan) that support the methods and findings reported in a manuscript. Individual de-identified participant data will be made available once the indication has been approved by a regulatory body, if there is participant consent and there is not a reasonable likelihood of participant re-identification.
Data sharing details ↗ · vivli.org
Ran from Mar 2019 to primary completion in Feb 2021, 23 months.
Results were first posted in May 2022, 1 year 3 months after primary completion.
Of 18 phase 2 interventional studies under Peanut Hypersensitivity, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's 23 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab